Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

French ePharmaDay 2015: New EU Clinical Trial Regulation and Data Transparency

Posted on November 24th, 2015 by

Pharmacovigilance

top_epharma

On 16 April 2014, the new EU Clinical Trial Regulation on medicines for human use was adopted. The purpose of the new Clinical Trial Regulation is to create an environment that is favourable for conducting clinical trials, with the highest standards for patient safety, within the EU. Continue reading “French ePharmaDay 2015: New EU Clinical Trial Regulation and Data Transparency” »

Express your “Pharma Pride”, Clearly Communicate Science

Posted on November 23rd, 2015 by

Pharma R&D

PP

Have you ever tried googling ‘Pharma Industry’? Right after Wikipedia, page after page, you will find various articles referring to ‘Getting High on Fat Profits’, ‘Holding Big Pharma Accountable’. Continue reading “Express your “Pharma Pride”, Clearly Communicate Science” »

David Evans Presents: Catching up with Reaxys PhD Prize winner Dr. Hiroyuki Miyamura

Posted on November 23rd, 2015 by

Chemistry

Dr Hiroyuki Miyamura

In a wide ranging interview, we find out what Reaxys PhD Prize Winner Dr. Hiroyuki Miyamura has been up to: Continue reading “David Evans Presents: Catching up with Reaxys PhD Prize winner Dr. Hiroyuki Miyamura” »

Can medicine mend a broken heart?

Posted on November 18th, 2015 by

Chemistry

broken-heart-cookie_lr

I freely admit, life without chocolate is unthinkable. That my daily sugar rush may lead to diabetes or blocked arteries (among other things) is something I prefer not to think about. Continue reading “Can medicine mend a broken heart?” »

Screening Scientific Literature for Adverse Drug Reactions: Relevant for Patient Safety or Just a Time-Consuming Regulatory Obligation?

Posted on November 16th, 2015 by

Pharmacovigilance

mag_glass_resized

An adverse drug reaction (ADR) is defined as any response to a medicinal product which is noxious and unintended. ADRs are a major public health problem, accounting for up to 5% of all hospital admissions and 28% of the emergency visits. Of all hospitalized patients, 5% experience an ADR during the hospitalization Continue reading “Screening Scientific Literature for Adverse Drug Reactions: Relevant for Patient Safety or Just a Time-Consuming Regulatory Obligation?” »

Eluding a Post-Antibiotic Era: The Challenge of Designing Novel Antibiotics

Posted on November 13th, 2015 by

Pharma R&D

MRSA bacteria. Computer artwork of methicillin-resistant Staphylococcus aureus (MRSA) bacteria.

As cases of drug-resistant pathogens multiply, the WHO warns of a “post-antibiotic era.” Designing novel antibiotics, however, remains a scientific challenge because achieving therapeutic efficacy requires painstaking testing of compound properties that often conflict. Continue reading “Eluding a Post-Antibiotic Era: The Challenge of Designing Novel Antibiotics” »

  1. 1
  2. 51
  3. 52
  4. 53
  5. 54
  6. 55


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.